Allenburys Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 08-11-2024
- Paid Up Capital ₹ 0.50 M
as on 08-11-2024
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.00 Cr
as on 08-11-2024
- Revenue -33.15%
(FY 2023)
- Profit -75.34%
(FY 2023)
- Ebitda -107.98%
(FY 2023)
- Net Worth -97.40%
(FY 2023)
- Total Assets -50.20%
(FY 2023)
About Allenburys Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹10.00 Cr.
Rubi Mukhopadhyay, Biswajit Pan, and Anand Parmanandka serve as directors at the Company.
- CIN/LLPIN
U93020WB2020PLC240519
- Company No.
240519
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
15 Oct 2020
- Date of AGM
05 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Allenburys Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rubi Mukhopadhyay  | Director | 15-Oct-2020 | Current |
| Biswajit Pan | Director | 15-Oct-2020 | Current |
| Anand Parmanandka | Director | 15-Oct-2020 | Current |
Financial Performance of Allenburys Pharma.
Allenburys Pharma Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 33.15% decrease. The company also saw a substantial fall in profitability, with a 75.34% decrease in profit. The company's net worth observed a substantial decline by a decrease of 97.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Allenburys Pharma?
In 2023, Allenburys Pharma had a public holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Alventa Pharma LimitedActive 8 years 2 monthsRubi Mukhopadhyay, Biswajit Pan and 1 more are mutual person
- Aleris Pharmaceuticals LimitedActive 3 years 7 months
Rubi Mukhopadhyay, Biswajit Pan and 1 more are mutual person
- Elder Laboratories LimitedActive 3 years 7 months
Rubi Mukhopadhyay, Biswajit Pan and 1 more are mutual person
- Nicholas Pharma India LimitedActive 3 years 9 months
Rubi Mukhopadhyay, Biswajit Pan and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 22 Dec 2023 | ₹10.00 Cr | Open |
How Many Employees Work at Allenburys Pharma?
Unlock and access historical data on people associated with Allenburys Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Allenburys Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Allenburys Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
